Loading...
AGTC logo

Applied Genetic Technologies CorporationNasdaqGM:AGTC 株式レポート

時価総額 US$12.6m
株価
n/a
私の公正価値
n/a
1Y-80.9%
7D4.8%
1D
ポートフォリオ価値
​
表示

Applied Genetic Technologies Corporation

NasdaqGM:AGTC 株式レポート

時価総額：US$12.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Applied Genetic Technologies（AGTC）株式概要

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. 詳細

AGTC ファンダメンタル分析
スノーフレーク・スコア
評価0/6
将来の成長2/6
過去の実績0/6
財務の健全性3/6
配当金0/6

報酬

収益は年間68.05%増加すると予測されています

リスク分析

収益が 100 万ドル未満 ( $325K )

キャッシュランウェイが1年未満である

US市場と比較して、過去 3 か月間の株価の変動が非常に大きい

意味のある時価総額がありません ( $13M )

+1 さらなるリスク

AGTC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Applied Genetic Technologies Corporation 競合他社

価格と性能

株価の高値、安値、推移の概要Applied Genetic Technologies
過去の株価
現在の株価US$0.39
52週高値US$2.83
52週安値US$0.23
ベータ1.58
1ヶ月の変化-4.23%
3ヶ月変化-1.85%
1年変化-80.89%
3年間の変化-86.79%
5年間の変化-89.78%
IPOからの変化-97.33%

最新ニュース

Seeking Alpha • Jul 26

AGTC receives positive feedback from FDA for manufacturing facility

Applied Genetic Technologies (NASDAQ:AGTC) said the U.S. Food and Drug Administration had provided favorable feedback on the current Good Manufacturing Practice (cGMP) design of AGTC’s manufacturing facility. The facility will support AGTC’s pipeline, including the late-stage development and potential commercialization of its eye diseases therapy like X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs. The company said initial operations at the facility are expected to begin in Q4 with GMP capabilities expected to be finalized in Q1 2023. "We expect the facility will also play an important role in support of our promising pipeline of additional clinical and pre-clinical programs," the company said. (AGTC) rose 1.3% premarket.
Seeking Alpha • Jul 12

Applied Genetic Technologies proposes stock offering to fund clinical trials

Applied Genetic Technologies (NASDAQ:AGTC) announced Tuesday it plans to initiate underwritten stock offering that will see the issue of its common shares and accompanying stock purchase warrants. The company intends to use the net proceeds for fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa program and its ongoing Phase 1/2 clinical trials in its Achromatopsia program, its preclinical development programs, investments in its manufacturing facility and for working capital and other general corporate purposes, including scheduled payments under its term loan with Hercules Capital, Inc. AGTC Shares fell 29% after-hours, Tuesday, to trade at $0.60. Earlier: Applied Genetic Technologies raised $9.8M in stock offering

Recent updates

Seeking Alpha • Jul 26

AGTC receives positive feedback from FDA for manufacturing facility

Applied Genetic Technologies (NASDAQ:AGTC) said the U.S. Food and Drug Administration had provided favorable feedback on the current Good Manufacturing Practice (cGMP) design of AGTC’s manufacturing facility. The facility will support AGTC’s pipeline, including the late-stage development and potential commercialization of its eye diseases therapy like X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs. The company said initial operations at the facility are expected to begin in Q4 with GMP capabilities expected to be finalized in Q1 2023. "We expect the facility will also play an important role in support of our promising pipeline of additional clinical and pre-clinical programs," the company said. (AGTC) rose 1.3% premarket.
Seeking Alpha • Jul 12

Applied Genetic Technologies proposes stock offering to fund clinical trials

Applied Genetic Technologies (NASDAQ:AGTC) announced Tuesday it plans to initiate underwritten stock offering that will see the issue of its common shares and accompanying stock purchase warrants. The company intends to use the net proceeds for fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa program and its ongoing Phase 1/2 clinical trials in its Achromatopsia program, its preclinical development programs, investments in its manufacturing facility and for working capital and other general corporate purposes, including scheduled payments under its term loan with Hercules Capital, Inc. AGTC Shares fell 29% after-hours, Tuesday, to trade at $0.60. Earlier: Applied Genetic Technologies raised $9.8M in stock offering
Seeking Alpha • Jan 12

Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022

AGTC-501 is being developed to treat patients with X-linked retinitis pigmentosa. Two near-term results are expected in Q2 and Q3 of 2022, respectively; they are 3-month results from the SKYLINE study and 24-month results from the phase 1/2 study using AGTC-501. Results from two phase 1/2 studies pediatric patients with Achromatopsia are expected in Q1 of 2022. Applied Genetic Technologies Corporation had $90.5 million cash as of September 30, 2021; enough cash to fund its operations into 2023.
Seeking Alpha • Dec 14

An Assessment Of Applied Genetic Technologies Corporation

In the spotlight today is a developmental concern called Applied Genetic Technologies Corporation. The company has several gene therapy candidates in its pipeline and numerous potential milestones in 2022. A full investment analysis is provided in the paragraphs below.
Seeking Alpha • Jul 15

Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk

Applied Genetic Technologies Corporation is a mid-clinical-stage biotechnology company developing genetic therapies for rare and debilitating diseases. AGTC's initial focus is on ophthalmology (study of medical conditions relating to the eye) where AGTC has active programs for X-linked retinitis pigmentosa, achromatopsia, and optogenetics. AGT Corporation is in a reasonable financial position evidenced by 2+ years of cash runway driven by a low-cash burn (TTM: -$53M) and cash of $111M (March 2021). XLRP is being targeted by AGTC's lead therapeutic, RPGR, currently in a Phase 2/3 Vista study (data expected: 3Q 22) and a Phase 1/2 expansion trial known as Skyline (data expected: 4Q 21). In summary, the author projects Applied Genetic Technologies Corporation as a high-risk "hold".
分析記事 • May 21

Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Feb 05

What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?

Every investor in Applied Genetic Technologies Corporation ( NASDAQ:AGTC ) should be aware of the most powerful...
分析記事 • Jan 06

Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Dec 11

What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...

株主還元

AGTCUS BiotechsUS 市場
7D4.8%2.4%1.1%
1Y-80.9%34.6%28.7%

業界別リターン: AGTC過去 1 年間で34.6 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: AGTCは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。

価格変動

Is AGTC's price volatile compared to industry and market?
AGTC volatility
AGTC Average Weekly Movement19.5%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

安定した株価: AGTCの株価は、 US市場と比較して過去 3 か月間で変動しています。

時間の経過による変動: AGTCの weekly volatility ( 20% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
1999102Sue Washeragtc.com

Applied Genetic Technologies Corporation 基礎のまとめ

Applied Genetic Technologies の収益と売上を時価総額と比較するとどうか。
AGTC 基礎統計学
時価総額US$12.62m
収益（TTM）-US$70.23m
売上高(TTM)US$325.00k
38.9x
P/Sレシオ
-0.2x
PER（株価収益率

AGTC は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
AGTC 損益計算書（TTM）
収益US$325.00k
売上原価US$21.76m
売上総利益-US$21.44m
その他の費用US$48.80m
収益-US$70.23m

直近の収益報告

Sep 30, 2022

次回決算日

該当なし

一株当たり利益（EPS）-2.19
グロス・マージン-6,596.62%
純利益率-21,610.46%
有利子負債／自己資本比率92.6%

AGTC の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2022/12/01 13:06
終値2022/11/30 00:00
収益2022/09/30
年間収益2022/06/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Applied Genetic Technologies Corporation 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10

アナリスト機関
James BirchenoughBMO Capital Markets Equity Research
Yun ZhongBrean Capital Historical (Janney Montgomery)
Yun ZhongBTIG